Necrosis News and Research

RSS

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

23 Feb 2015

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation.

19 Feb 2015

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

17 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen.

9 Feb 2015

New compound may lead to development of potential therapeutics for neuropathic pain

A new compound discovered by a team of UC Davis investigators has potent actions against production of a chemical that which is implicated in the development of chronic pain following a peripheral nerve injury in the spinal cord.

7 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Scientists investigate how T cells in colorectal tumors actively fight cancer

In recent years, a standard follow-up to colorectal cancer surgery has been to analyze the tumor tissue for the presence of immune cells. Finding high quantities of cytotoxic T cells, or "killer cells", means that there is a good chance that the disease will take a favorable course and that the risk of metastasis is comparatively low.

5 Feb 2015

Mathematical models of cancer behavior offer new insights on tumor growth

Hassan Fathallah-Shaykh, M.D., Ph.D., believes that math can transform medicine, and he has the numbers to prove it.

2 Feb 2015

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

New trial shows efficacy of PrimiCell product on muscle repair

BioAdaptives, Inc. announced results of the recently completed in vivo trial showing the efficacy of its PrimiCell product on muscle repair.

8 Dec 2014

Scientists unravel molecular mechanisms that drive ferroptosis signaling

Ferroptosis is a recently recognized form of regulated necrosis. Up until now, this form of cell death has only been thought to be a possible therapeutic approach to treat tumour cells. Yet, ferroptosis also occurs in non-transformed tissues as demonstrated by this study, thus implicating this cell death pathway in the development of a wide range of pathological conditions. More specifically, the deletion of the ferroptosis-regulating enzyme Gpx4 in a pre-clinical model results in high ferroptosis rates in kidney tubular epithelial cells causing acute renal failure.

19 Nov 2014

EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF, has entered a collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers.

From EKF Diagnostics 17 Nov 2014

Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

ACS is currently identified through the use of ECGs pre-hospital and the confirmed via a Troponin biomarker test once in the acute setting.

16 Nov 2014

Sarcomatoid differentiation levels predict poor RCC survival

Research shows that the degree of sarcomatoid differentiation in patients with grade 4 renal cell carcinoma is not only associated with poor survival, but can also serve as an independent prognostic factor in these patients.

14 Nov 2014

UCSD researchers describe surprising role of protein in embryonic development

Hematopoietic stem cells (HSCs) give rise to all blood and immune cells throughout the life of vertebrate organisms, from zebrafish to humans. But details of their genesis remain elusive, hindering efforts to develop induced pluripotent stem cell (iPSC) replacements that might address a host of blood disorders.

7 Nov 2014

TNF-α key player in RCC progression

Tumour necrosis factor - α appears to play a key role in the promotion of invasion and metastasis in clear cell renal cell carcinomas, Japanese study findings indicate.

30 Oct 2014